Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ertapenem vs Piperacillin/Tazobactam in Diabetic Foot Infections
NCT01370616Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2011
- Primary completion
- Dec 2013
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of ertapenem in diabetic foot infection (DFI), sponsored by Merck & Co.. Started Sep 2011; status: completed.
02
Drugs
ertapenem
03
Conditions
diabetic foot infection (DFI)
Beyond the preview
Go deeper on NCT01370616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01370616.